SILVER SPRING, Md., July 2 (Reuters) - U.S. regulators should require drugmakers to study the potential heart risks of all new diabetes medicines, an advisory panel said on Wednesday.
SILVER SPRING, Md., July 2 (Reuters) - U.S. regulators should require drugmakers to study the potential heart risks of all new diabetes medicines, an advisory panel said on Wednesday.